allogeneic– tag –
-
New Market Pitch Evaluates Top Cell Therapy Startups Including Orca Bio, Cellares, and Kelonia: Differentiated by Clinical, Manufacturing, and Strategic Advancements
New Market Pitch USA Overview New Market Pitch selected ten leading cell therapy startups—Orca Bio, Kyverna, Cabaletta Bio, Cellares, Immatics, Iovance, Sana, Kelonia, Orna, and Dispatch Bio—evaluating their regulatory maturity, clinical... -
Nkarta Accelerates Clinical Development of Off-the-Shelf NK Cell Therapies NKX019 and NKX101 from Healthy Donors
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, focuses on off-the-shelf natural killer (NK) cell therapies, utilizing a platform that genetically engineers and cryopreserves healthy donor-derived NK cells. Its lead p... -
Frontiers Reports GMP-Compliant Scalable Manufacturing Platform Established for Allogeneic Type 1 Regulatory T Cells (TRX103)
Frontiers in Immunology Switzerland Overview A study published in Frontiers reports the establishment of a GMP-compliant, scalable manufacturing platform for TRX103, an allogeneic Type 1 regulatory T cell (Tr1 cell). While TRX103 has sho... -
Orca Bio Expands East Coast Manufacturing Capacity and Triples West Coast Workforce Ahead of Potential Orca-T® Commercial Launch, with FDA PDUFA Date Set for July 6, 2026
Business Wire USA Overview Orca Bio announced significant manufacturing expansions for its investigational cell therapy, Orca-T®, in anticipation of its commercial launch. This includes establishing new East Coast manufacturing capacity ... -
Qihan Biotech’s Universal Dual-Target Hypoimmune CAR-T Therapy QT-019B Receives FDA RMAT and Breakthrough Therapy Designations
PackGene Biotech China Overview Qihan Biotech's universal dual-target CAR-T therapy, QT-019B, has received both FDA Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy Designations (BTD). This off-the-shelf allogeneic ... -
FDA Grants RMAT Designation to Cellectis’ Allogeneic CD22 CAR-T Lasme-cel for Relapsed/Refractory B-ALL
Targeted Oncology USA Overview The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Cellectis' lasmecabtagene timgedleucel (lasme-cel; UCART22), an allogeneic CD22-targeting CAR-T cell therapy, for relapsed/re... -
Preprint Reviews NKG2D CAR-NK Cell Progress in Cancer Immunotherapy: Low GVHD Risk, Scalable Manufacturing, and iPSC-Derived NK Cells as a Platform for Off-the-Shelf Therapies
Preprints.org International Overview A preprint on Preprints.org reviews recent progress in NKG2D CAR-NK cells for cancer immunotherapy, highlighting their favorable safety profile with rare instances of graft-versus-host disease (GVHD) ... -
CombiCult® Platform Boosts iPSC-Derived NK Cell Production 10-Fold in Stirred-Tank Bioreactors for Allogeneic Solid Tumor Therapy
Frontiers Switzerland Overview A study published in Frontiers has identified a feeder-free, manufacturable protocol for generating iPSC-derived NK (iNK) cells using the CombiCult® high-throughput screening platform. Scaling up to stirred... -
CombiCult® Screening Platform Establishes Feeder-Free Bioreactor Scalability for iPSC-Derived NK Cell Manufacturing
Frontiers (Preprint) Germany Overview This preprint reports research developing a feeder-free protocol for generating mature, functional iPSC-derived natural killer (iNK) cells using the high-throughput combinatorial screening platform C... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un...
